Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
May 01 2020 - 6:00AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease, Parkinson’s
disease and other neurodegenerative diseases, announced
today an interview with CEO Maria Maccecchini, Ph.D., will air
on The RedChip Money Report television program. The interview will
air Sunday, May 3, at 3 p.m. local time on Bloomberg International,
available in 100+ million homes across Europe.
In the exclusive interview, Dr. Maccecchini provides an overview
of the Company’s clinical trial programs and upcoming
milestones.
To view the interview segment, please visit:
https://youtu.be/QxqQE2NgI8A
The interview will also air in the US on the Family Channel on
May 6 at 6 p.m., the Action Channel on Sunday May 3 at 11 a.m. and
is available via on demand stream on American Business TV.
“The RedChip Money Report" delivers insightful commentary on
small-cap investing, interviews with Wall Street analysts,
financial book reviews, as well as featured interviews with
executives of public companies.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc.
(Annovis) is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s
disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe
that we are the only company developing a drug for AD, PD and AD-DS
that inhibits more than one neurotoxic protein and, thereby,
improves the information highway of the nerve cell, known as axonal
transport. When this information flow is impaired, the nerve cell
gets sick and dies. We expect our treatment to improve memory loss
and dementia associated with AD and AD-DS, as well as body and
brain function in PD. We have an ongoing Phase 2a study in AD
patients and plan to commence a second Phase 2a study in PD
patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words, and
include, without limitation, statements regarding the timing,
effectiveness and anticipated results of ANVS401 clinical trials.
Forward-looking statements are based on Annovis Bio, Inc.’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:
Dave Gentry, CEO RedChip Companies Inc. 407-491-4498
Dave@redchip.com
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Apr 2023 to Apr 2024